These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1454 related articles for article (PubMed ID: 25207767)

  • 1. Pancreatic adenocarcinoma.
    Ryan DP; Hong TS; Bardeesy N
    N Engl J Med; 2014 Sep; 371(11):1039-49. PubMed ID: 25207767
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 4. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
    Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
    Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer research matures.
    Nelson NJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
    [No Abstract]   [Full Text] [Related]  

  • 7. Targets, trials, and travails in pancreas cancer.
    Izeradjene K; Hingorani SR
    J Natl Compr Canc Netw; 2007 Nov; 5(10):1042-53. PubMed ID: 18053428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies.
    Fuccio L; Hassan C; Laterza L; Correale L; Pagano N; Bocus P; Fabbri C; Maimone A; Cennamo V; Repici A; Costamagna G; Bazzoli F; Larghi A
    Gastrointest Endosc; 2013 Oct; 78(4):596-608. PubMed ID: 23660563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.
    Mancuso A; Sollami R; Recine F; Cerbone L; Macciomei MC; Leone A
    J Clin Oncol; 2010 Dec; 28(36):e756-8. PubMed ID: 20855834
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic and epigenetic markers in the evaluation of pancreatic masses.
    Ginestà MM; Mora J; Mayor R; Farré A; Peinado MA; Busquets J; Serrano T; Capellá G; Fabregat J
    J Clin Pathol; 2013 Mar; 66(3):192-7. PubMed ID: 23135349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
    Ohtsubo K; Ishikawa D; Nanjo S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Yasumoto K; Gabata T; Matsui O; Ikeda H; Takamatsu Y; Iwakami S; Yano S
    JOP; 2013 Sep; 14(5):515-20. PubMed ID: 24018598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
    Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
    J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraductal tubular carcinoma of the pancreas: case report with molecular analysis.
    Furukawa T; Hatori T; Fukuda A; Fujita I; Yamamoto M
    Pancreas; 2009 Mar; 38(2):235-7. PubMed ID: 19238030
    [No Abstract]   [Full Text] [Related]  

  • 15. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
    Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
    Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
    [No Abstract]   [Full Text] [Related]  

  • 16. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
    J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
    [No Abstract]   [Full Text] [Related]  

  • 18. [Responses to targeted therapies: colorectal cancer].
    Bibeau F; Frugier H; Boissière-Michot F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S74-6. PubMed ID: 19887260
    [No Abstract]   [Full Text] [Related]  

  • 19. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
    Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
    Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Strimpakos AS; Saif MW
    JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.